《大行報告》中金下調思摩爾(06969.HK)目標價至10元 評級「跑贏行業」
中金發表報告指,思摩爾(06969.HK)上半年業績符合該行預期,看好公司作為全球霧化科技龍頭的創新能力與競爭優勢,下半年業績有望迎來改善。
該行預計,隨美國市場執法趨嚴、國內市場修覆、一次性與CBD等新品放量,下半年業績有望環比改善;且公司堅持研發創新護航中長期成長,HNB、霧化醫療等新領域有望迎來成功打造。
基於國內市場仍明顯承壓,中金下調思摩爾今明兩年盈利預測各21%和20%至18.6億和25億元人民幣,維持「跑贏行業」評級,考慮盈利預測調整及中長期成長空間,下調目標價9%至10港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.